Welcome subscribers,
Europe's life sciences real estate has grown into an €8.4 billion (£7.1 billion) market across 240 deals in 15 countries, with success tied to operational excellence and specialised expertise. Meanwhile, investment in research, production and distribution facilities continues apace. Read our analysis, along with the latest property transactions, from new builds to acquisitions:
✅ Ireland: WuXi sells to Merck
✅ Netherlands: Deka buys logistics asset
✅ Spain: Arkéa acquires innovation campus
✅ UK: £25 million King's Cross loan
Read more below for all the details.
€8.4 billion and counting: Four years of life sciences real estate deals in Europe
We reflect on the trends and milestones from 2021 to 2024 and explore the drivers behind the sector's growth, the key investment strategies, and the insights that have shaped its trajectory.
Transactions
CZECHIA BOHUMIL
In December 2024 vaccine-maker Novavax said it is selling a manufacturing plant in the Czech Republic to Novo Nordisk for $200 million (€192 million / £167 million). The 14,000 sq m (150,000 sq ft) Bohumil site currently manufactures recombinant proteins used in vaccines. Novo Nordisk has acquired the facility along with all its support infrastructure and an existing workforce of 150 employees. The facility will not be used to make Ozempic and Wegovy.
GERMANY BERLIN
In October 2024, VALUES Real Estate acquired the medical centre H87 Health Center Friedenau in the Berlin district of the same name in the southwest of the city. The property consists of a two-part, fully-leased building at Hauptstraße 87. The centre has more than 2,700 sq m (29,100 sq ft) of rental space, which is leased on a long-term basis to a total of nine medical specialists, a dialysis centre, and a hearing aid specialist. It will become part of the institutional fund VALUES Health Invest I. The purchase price was not disclosed.
GERMANY MUNICH
The Metzingen-based robotics company NEURA Robotics has moved into a 500 sq m (5,400 sq ft) rental space in South Horizon Munich (SOHO Munich). The company operates across multiple sectors, with a strong focus on healthcare, where its robots perform tasks ranging from logistics to surgical assistance. NEURA's solutions include cleaning, disinfection, and transport operations designed to reduce pathogen transmission risks. (NEURA Robotics announced on 15 January that it has raised €120 million (£102 million) in a Series B funding round.)
